Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label study of BL-M07D1 versus trastuzumab deruxtecan in HR-positive HER2-low recurrent or metastatic breast cancer
CTR20262483Phase 2Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Sep 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of BL-M07D1, trastuzumab deruxtecan in breast cancer, sponsored by Biokin Pharmaceutical. Started Sep 2026; status: active.
02
Drugs
BL-M07D1trastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20262483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262483.